CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to ...

Most students who applied for South Carolina’s private K-12 tuition aid program this year were either already attending ...

Please note that the limited information that follows in this press release is not adequate to make an informed investment ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

Diluted earnings per share ("EPS") of $0.77Invested $72 million in water and wastewater utility infrastructure during the nine months ended September 30, 2025, or approximately 77% of the 2025 capital ...

Law Reform Commission to propose a statutory compensation scheme for victims of crime, including payments for pain and ...

Good morning, and welcome to IPG Photonics Third Quarter 2025 Conference Call. Today's call is being recorded and webcast. At this time, I'd like to turn the call over to your host, Eugene Fedotoff, ...

Neuropace, Inc. ( ($NPCE) ) has released its Q3 earnings. Here is a breakdown of the information Neuropace, Inc. presented to its investors.

2- Although the results for the nine months ending September 30, 2025, still show losses, the improved results in the third ...

Q3 2025 Earnings Call October 31, 2025 4:00 AM EDTCompany ParticipantsBernt Omdal - Chief Executive OfficerVidar Jerstad ...